Your browser doesn't support javascript.
loading
Cost-consequence analysis of Pharmaceutical Care program for systemic arterial hypertension in the public health system in Brazil
Cazarim, Maurílio de Souza; Nunes, Altacílio Aparecido; Pereira, Leonardo Régis Leira.
Afiliação
  • Cazarim, Maurílio de Souza; University of São Paulo. School of Pharmaceutical Sciences of Ribeirão Preto. Department of Pharmaceutical Sciences. Ribeirão Preto. BR
  • Nunes, Altacílio Aparecido; University of São Paulo. School of Medicine. Department of Social Medicine. Ribeirão Preto. BR
  • Pereira, Leonardo Régis Leira; University of São Paulo. School of Pharmaceutical Sciences of Ribeirão Preto. Department of Pharmaceutical Sciences. Ribeirão Preto. BR
Braz. J. Pharm. Sci. (Online) ; 53(3): e00217, 2017. tab, graf
Article em En | LILACS | ID: biblio-889393
Biblioteca responsável: BR40.1
Localização: BR40.1
ABSTRACT
ABSTRACT In Brazil, 80% of hypertensive patients have no blood pressure controlled, this fact has caused severe financial consequences for the public health system (PHS) and the Pharmaceutical Care (PC) has emerged as an effective alternative. The aim of this study was to analyze the costs and outcomes of systemic arterial hypertension (SAH) for conventional assistance compared to assistance with PC in the PHS. This is a pharmacoeconomic study with cost-consequence analysis nested to clinical trial. Hypertensives patients were followed-up from 2006 to 2012. During 2009 they were assisted by the PC program in Ribeirão Preto-SP, Brazil. Clinical indicators, systolic and diastolic blood pressure (SBP and DBP), triglycerides, total cholesterol (TC) and its fractions and healthcare indicators, consumption of antihypertensive medication and consultations were analyzed. Costs were listed as direct medical and direct non-medical. The average cost of conventional care for 104 patients followed-up was US$ 198.97, in the PC period and after discharge was US$ 407.91 and US$ 214.96 patient/year. After discharge of patients from PC there was reduction of SBP, DBP, TC and cardiovascular risk, 9.4 mmHg, 4.6 mmHg, 12.0 mg/dL, and 23% [p<0.005], respectively. The PC program optimized clinical and healthcare indicators and impacted in the SAH costs for the PHS.
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: LILACS Assunto principal: Gastos em Saúde / Custos e Análise de Custo / Hipertensão Tipo de estudo: Clinical_trials / Health_economic_evaluation Limite: Female / Humans País/Região como assunto: America do sul / Brasil Idioma: En Revista: Braz. J. Pharm. Sci. (Online) Assunto da revista: Farmacologia / Terapˆutica / Toxicologia Ano de publicação: 2017 Tipo de documento: Article / Project document País de afiliação: Brasil País de publicação: Brasil
Texto completo
Adicionar na Minha BVS
Imprimir
XML
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: LILACS Assunto principal: Gastos em Saúde / Custos e Análise de Custo / Hipertensão Tipo de estudo: Clinical_trials / Health_economic_evaluation Limite: Female / Humans País/Região como assunto: America do sul / Brasil Idioma: En Revista: Braz. J. Pharm. Sci. (Online) Assunto da revista: Farmacologia / Terapˆutica / Toxicologia Ano de publicação: 2017 Tipo de documento: Article / Project document País de afiliação: Brasil País de publicação: Brasil